Literature DB >> 30955709

Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system.

Terezia Kiskova1, Yuliya Mytsko1, Martin Schepelmann1, Hanns Helmer2, Renate Fuchs1, Heidi Miedl3, Christian Wadsack4, Isabella Ellinger5.   

Abstract

INTRODUCTION: Starting from the second trimester of pregnancy, passive immunity is provided to the human fetus by transplacental transfer of maternal IgG. IgG transfer depends on the neonatal Fc receptor, FcRn. While FcRn localization in the placental syncytiotrophoblast (STB) has been demonstrated unequivocally, FcRn expression in placental-fetal endothelial cells (pFECs), which are part of the materno-fetal barrier, is still unclear. Therefore, this study aimed to elucidate the spatio-specific expression pattern of FcRn in placental tissue.
METHODS: FcRn expression was investigated by western blotting in term placentas and in isolated human placental arterial and venous endothelial cells (HPAEC, HPVEC) using a validated affinity-purified polyclonal anti-peptide antibody against the cytoplasmic tail of FcRn α-chain. In situ localization of FcRn and IgG was studied by immunofluorescence microscopy on tissue sections of healthy term placentas.
RESULTS: FcRn expression was demonstrated in placental vasculature particularly, in HPAEC, and HPVEC. FcRn was localized in cytokeratin 7+ STB and in CD31+ pFECs in terminal as well as stem villi in situ. Additionally, CD68+ placental macrophages exhibited FcRn expression in situ. Endogenous IgG partially co-localized with FcRn in STB, pFECs, and in placental macrophages. DISCUSSION: Placental FcRn expression in endothelial cells and macrophages is analogous to the expression pattern in other organs. FcRn expression in pFECs suggests an involvement of FcRn in IgG transcytosis and/or participation in recycling/salvaging of maternal IgG present in the fetal circulation. FcRn expression in placental macrophages may account for recycling of monomeric IgG and/or processing and presentation of immune complexes.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FcRn; Human placenta; IgG transport; Placental macrophages; Placental-fetal endothelial cells; Syncytiotrophoblast

Mesh:

Substances:

Year:  2019        PMID: 30955709     DOI: 10.1016/j.placenta.2019.02.012

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  6 in total

1.  HIV-Associated Alterations of the Biophysical Features of Maternal Antibodies Correlate With Their Reduced Transfer Across the Placenta.

Authors:  Sean A Taylor; Shilpee Sharma; Christopher A L Remmel; Beth Holder; Christine E Jones; Arnaud Marchant; Margaret E Ackerman
Journal:  J Infect Dis       Date:  2022-10-17       Impact factor: 7.759

Review 2.  Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy.

Authors:  Katherine L Gill; Hannah M Jones
Journal:  AAPS J       Date:  2022-06-01       Impact factor: 3.603

Review 3.  Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance.

Authors:  Angelina Mimoun; Sandrine Delignat; Ivan Peyron; Victoria Daventure; Maxime Lecerf; Jordan D Dimitrov; Srinivas V Kaveri; Jagadeesh Bayry; Sébastien Lacroix-Desmazes
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

4.  Post-Vaccination Yellow Fever Antiserum Reduces Zika Virus in Embryoid Bodies When Placental Cells are Present.

Authors:  Emily M Schultz; TyAnthony J Jones; Hannah K Hopkins; Jingmei Zeng; Kelli L Barr
Journal:  Vaccines (Basel)       Date:  2020-12-11

Review 5.  In Translation: FcRn across the Therapeutic Spectrum.

Authors:  Timothy Qi; Yanguang Cao
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

6.  Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors.

Authors:  Toby Clements; Thomas F Rice; George Vamvakas; Sara Barnett; Megan Barnes; Beverly Donaldson; Christine E Jones; Beate Kampmann; Beth Holder
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.